Myocard2.5 mg

Myocard 2.5 mg tablets are indicated for the treatment of the following conditions:

• Hypertension (high blood pressure)
• Angina pectoris (chest pain caused by reduced blood flow to the heart)
• Moderate to severe chronic heart failure, usually as part of combination therapy

Myocard 2.5 mg is not recommended for the emergency management of hypertensive crises, as its onset of action is not rapid enough for acute blood pressure control.

Myocard 2.5 mg is regarded as one of the most β1-selective beta-blockers currently available, showing a stronger affinity for β1 receptors than most other beta-blocking agents. By selectively blocking β1 adrenergic receptors in the heart and vascular smooth muscle, Bisoprolol reduces heart rate and cardiac output, which in turn lowers arterial blood pressure.

Unlike non-selective beta-blockers, which can negatively affect lipid metabolism, Bisoprolol does not significantly alter cholesterol fractions, including cardioprotective HDL cholesterol, even with long-term use. Its favorable pharmacokinetic profile supports a single daily dose with minimal variation in plasma concentration between individuals and across dosing intervals, contributing to its high therapeutic reliability.

Absorption and Bioavailability

Bisoprolol is almost completely absorbed (more than 90%) from the gastrointestinal tract. Combined with a small first-pass hepatic effect (less than 10%), this results in an absolute bioavailability of approximately 88%. Taking Bisoprolol with food does not affect its absorption.

Distribution

Bisoprolol is extensively distributed throughout body tissues, with an average volume of distribution of approximately 3.5 L/kg.

Metabolism

Bisoprolol undergoes oxidative metabolism without further conjugation. All resulting metabolites are highly polar and are eliminated through the kidneys. Studies using human liver microsomes indicate that Bisoprolol is metabolized mainly via the CYP3A4 enzyme pathway (approximately 95%), with CYP2D6 playing only a minor role. Its major metabolites have no significant pharmacological activity.

Elimination

Bisoprolol is cleared from the body through a balanced combination of renal excretion of the unchanged drug (about 50%) and hepatic metabolism (about 50%), with the resulting metabolites also excreted renally. Total clearance is approximately 15 L/hour, and the elimination half-life ranges from 10 to 12 hours, supporting its once-daily dosing schedule.

Other Beta-Blocking Agents

Myocard 2.5 mg should not be used together with other beta-blocking medications, as this can lead to excessive beta-blockade.

Catecholamine-Depleting Drugs

Patients taking catecholamine-depleting medications such as reserpine or guanethidine should be closely monitored, since the combined beta-blocking effects may cause an excessive reduction in sympathetic nervous system activity, potentially leading to hypotension or bradycardia.

Centrally Active Antihypertensive Agents

Beta-blockers may worsen the rebound hypertension that can occur when clonidine is discontinued. If both drugs are used together, the beta-blocker should be stopped several days before clonidine is withdrawn. When switching from clonidine to a beta-blocker, initiation of the beta-blocker should be delayed for several days after clonidine has been discontinued.

Antiarrhythmic Agents

Caution is advised when Myocard 2.5 mg is used concurrently with myocardial depressants or drugs that inhibit atrioventricular (A-V) conduction, such as certain calcium channel blockers (verapamil, diltiazem) or antiarrhythmic agents like disopyramide.

Calcium Channel Blockers

Combining beta-blockers with calcium channel blockers that have negative inotropic effects can prolong S-A and A-V conduction, particularly in patients with pre-existing ventricular dysfunction or conduction abnormalities. This combination may result in severe hypotension, bradycardia, or cardiac failure.

As with any medicine, Myocard 2.5 mg can cause side effects in some individuals, although not everyone will experience them. Reported side effects include:

• Fatigue and tiredness
• Dizziness
• Headache
• Gastrointestinal disturbances, including nausea, vomiting, diarrhea, constipation, or abdominal pain
• Cold or numb extremities, such as hands and feet
• Muscle weakness or cramps
• Slower than normal heart rate (bradycardia)
• Breathing difficulties due to airway narrowing (bronchospasm), particularly in people with asthma or COPD

If any side effect becomes severe or persistent, patients should consult their physician promptly.

Pregnancy

In animal studies, Myocard 2.5 mg was not teratogenic in rats at doses up to 150 mg/kg/day (375 times the maximum recommended human daily dose), although it caused fetotoxicity (increased late resorptions) at 50 mg/kg/day and maternal toxicity at 150 mg/kg/day. In rabbits, it was not teratogenic at doses up to 12.5 mg/kg/day (31 times the maximum human dose) but was embryolethal at that dose. There are no adequate studies in pregnant women, so Myocard 2.5 mg should be used during pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus.

Lactation

Small amounts of Myocard 2.5 mg (less than 2% of the maternal dose) have been detected in the milk of lactating rats. It is not known whether Bisoprolol is excreted in human breast milk. If treatment with Myocard 2.5 mg is considered essential during breastfeeding, discontinuation of nursing may be advised by the treating physician.

• Use with caution in patients with impaired renal or hepatic function, and adjust the dose accordingly.
• Patients with a history of severe anaphylactic reactions to various allergens may become more sensitive to repeated exposure while taking beta-blockers, whether the exposure is accidental, diagnostic, or therapeutic.
• Such patients may not respond adequately to the usual doses of epinephrine used to treat severe allergic reactions.
• Bisoprolol may mask the warning signs of low blood sugar (hypoglycemia) in diabetic patients, so blood glucose levels should be monitored regularly.
• Myocard 2.5 mg may cause dizziness; patients should rise slowly from a sitting or lying position to reduce the risk of falls.
• Never discontinue Myocard 2.5 mg abruptly without medical advice, as sudden withdrawal can cause a rebound increase in blood pressure and heart rate, raising the risk of angina, heart attack, or stroke.

• Store in a cool, dry place, away from direct light and heat.
• Keep the medicine in its original packaging until ready to use.
• Keep out of the reach of children and pets.